Cardiocore CMO presents at the Society of Toxicology 48th Annual Meeting

Washington, DC – 23.February.2009 – Cardiocore, a premier centralized cardiac testing lab, announced today that its Chief Medical Officer, Dr. Lawrence Satin, MD, FACC, will discuss the evaluation of QT prolongation and Torsades de pointes in accordance with ICH S7B and E14 guidelines, at the Society of Toxicology 48th Annual Meeting, on March 17th, at the Baltimore Convention Center, in Baltimore, Maryland.

At the meeting, Dr. Satin, one of the world’s leading research cardiologists and a pioneer in cardiac safety testing for clinical trials, will present Current Status of Pre-Clinical Assessment of Cardiac Safety in the Development of Non-Cardiac Drugs, and the Latest Update to The Guidance for Industry E-14.

Although a negative integrated pre-clinical assessment does not negate the need to evaluate the cardiac safety of new chemical entities in the United States, concern remains high for the continued industry practice of abolishing exploratory development of new compounds on the basis of a single positive hERG test. In November 2008, the FDA Interdisciplinary Review Team for QT assessment issued a clarification to the original E-14 Guidance for Industry, that was originally published in October 2005. Dr. Satin’s discussion will examine the potential impact of this latest update on the conduct of Through QT trials.

Details about this SOT meeting may be accessed through Cardiocore’s web site at http://www.cardiocore.com/news/events/.